Asklepios Biopharmaceutical, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.askbio.com
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
- Conditions
- Parkinson Disease
- Interventions
- Drug: AAV2-GDNF Gene therapyProcedure: Control Surgery
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AskBio Inc
- Target Recruit Count
- 87
- Registration Number
- NCT06285643
- Locations
- 🇺🇸
UCI Alpha Clinic (Neurology), Irvine, California, United States
🇺🇸Loma Linda University (Neurology), Loma Linda, California, United States
🇺🇸Loma Linda University (Surgical), Loma Linda, California, United States
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
- Conditions
- Multiple System Atrophy, Parkinson VariantParkinson's DiseaseMultiple System Atrophy
- Interventions
- Other: This is an observational study.
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Asklepios Biopharmaceutical, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT05699460
- Locations
- 🇵🇱
Samodzielny Publiczny Szpital Kliniczny im. prof. Witolda Orłowskiego, Oddział Neurologii i Epileptologii, Warszawa, Poland
🇵🇱Specjalistyczna Praktyka Lekarska, Prof. Grzegorz Opala, Katowice, Poland
🇺🇸University of California Irvine, Irvine, California, United States
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AskBio Inc
- Target Recruit Count
- 150
- Registration Number
- NCT05598333
- Locations
- 🇳🇱
Erasmus Medisch Centrum, Rotterdam, Netherlands
🇪🇸Hospital Universitario de Bellvitge, Barcelona, Catalogna, Spain
🇺🇸Cardiology P.C. Birmingham, Birmingham, Alabama, United States
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
- Conditions
- Muscular DystrophyFukutin Related ProteinLimb-Girdle Muscular Dystrophy Type 2LGMD2LGMDFKRPFKRP MutationLimb Girdle Muscular DystrophyLGMD2I
- Interventions
- Genetic: AB-1003 dose level 2Genetic: AB-1003 dose level 1Other: Placebo
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Asklepios Biopharmaceutical, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05230459
- Locations
- 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
AB-1002 in Patients With Class III Heart Failure
- Conditions
- Congestive Heart FailureHeart Failure, DiastolicHeart; ComplicationsHeart Disease, IschemicHeart Failure, SystolicHeart FailureCardiovascular DiseasesHeart Failure，CongestiveHeart Arrhythmia
- Interventions
- Biological: 3 x 10e13vg NAN-101Biological: 3 x 10e13vg AB-1002
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AskBio Inc
- Target Recruit Count
- 17
- Registration Number
- NCT04179643
- Locations
- 🇺🇸
Minneapolis Heart Foundation Institute, Minneapolis, Minnesota, United States
🇺🇸The Linder Center for Education and Research at The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease
- Conditions
- Pompe Disease
- Interventions
- Biological: ACTUS-101
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Asklepios Biopharmaceutical, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03533673
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States